INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45m ago
HOUSE PTR5m ago
SEC 13F5m ago
ROBINHOOD CHAIN5m ago
SEC FORM 4/Open-market saleVerified data

Tamayo Louis Edward sold LXEO

Chief Financial Officer · Lexeo Therapeutics, Inc. · Common Stock

Side
SELL
Value
$21K
Shares
4,641
Price
$4.49
Executed
Jul 1, 2026
Disclosed
Jul 1, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Jul 1 executedJul 1, 2026 disclosed

LXEO · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
36/ 100 · ELEVATED
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+1 / 25

    $21K reported value · 4.6% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+15 / 15

    3 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · LXEO

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    2
    TN
    Townsend Richard NolanDirector, Chief Executive Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    145.5K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    15
    OM
    Otero Jose ManuelChief Operating Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A$5,579
    2,110 sh
    		Sep 14, 2026Sep 28, 2026
    traded Sep 14, 2026
    		+14dSEC FORM 4

    Evidence

    5
    OM
    Otero Jose ManuelChief Operating Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    54.8K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    15
    BP
    Bhalla Narinder PalChief Medical Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A$9,713
    2,714 sh
    		Sep 14, 2026Sep 28, 2026
    traded Sep 14, 2026
    		+14dSEC FORM 4

    Evidence

    5
    BP
    Bhalla Narinder PalChief Medical Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    54.8K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    5
    TE
    Tamayo Louis EdwardChief Financial Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    54.8K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    12
    TN
    Townsend Richard NolanDirector, Chief Executive Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A$6,097
    2,306 sh
    		Sep 14, 2026Sep 28, 2026
    traded Sep 14, 2026
    		+14dSEC FORM 4

    Evidence

    27
    OM
    Otero Jose ManuelChief Operating Officer
    LXEOLexeo Therapeutics, Inc.
    Open-market sale
    		SELL$6,464
    1,304 sh
    		Aug 18, 2026Aug 19, 2026
    traded Aug 18, 2026
    		+1dSEC FORM 4

    Evidence

    27
    TN
    Townsend Richard NolanDirector, Chief Executive Officer
    LXEOLexeo Therapeutics, Inc.
    Open-market sale
    		SELL$17K
    3,345 sh
    		Aug 18, 2026Aug 19, 2026
    traded Aug 18, 2026
    		+1dSEC FORM 4

    Evidence

    27
    TE
    Tamayo Louis EdwardChief Financial Officer
    LXEOLexeo Therapeutics, Inc.
    Open-market sale
    		SELL$20K
    4,117 sh
    		Aug 18, 2026Aug 19, 2026
    traded Aug 18, 2026
    		+1dSEC FORM 4

    Evidence

    39
    TN
    Townsend Richard NolanDirector, Chief Executive Officer
    LXEOLexeo Therapeutics, Inc.
    Open-market sale
    		SELL$116K
    25.9K sh
    		Jul 1, 2026Jul 1, 2026
    traded Jul 1, 2026
    		+0dSEC FORM 4

    Evidence

    9
    TN
    Townsend Richard NolanDirector, Chief Executive Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    67.0K sh
    		Jun 29, 2026Jul 1, 2026
    traded Jun 29, 2026
    		+2dSEC FORM 4

    Evidence

    32
    OM
    Otero Jose ManuelChief Operating Officer
    LXEOLexeo Therapeutics, Inc.
    Open-market sale
    		SELL$21K
    4,666 sh
    		Jul 1, 2026Jul 1, 2026
    traded Jul 1, 2026
    		+0dSEC FORM 4

    Evidence

    9
    OM
    Otero Jose ManuelChief Operating Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    12.1K sh
    		Jun 29, 2026Jul 1, 2026
    traded Jun 29, 2026
    		+2dSEC FORM 4

    Evidence

    13
    TE
    Tamayo Louis EdwardChief Financial Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    12.0K sh
    		Jun 29, 2026Jul 1, 2026
    traded Jun 29, 2026
    		+2dSEC FORM 4

    Evidence

    47
    BP
    Bhalla Narinder PalChief Medical Officer
    LXEOLexeo Therapeutics, Inc.
    Open-market sale
    		SELL$99K
    22.3K sh
    		Jul 1, 2026Jul 1, 2026
    traded Jul 1, 2026
    		+0dSEC FORM 4

    Evidence

    21
    BP
    Bhalla Narinder PalChief Medical Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    55.0K sh
    		Jun 29, 2026Jul 1, 2026
    traded Jun 29, 2026
    		+2dSEC FORM 4

    Evidence

    9
    AK
    Agger Mette KirstineDirector
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    35.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    CB
    Cooperstone BrendaDirector
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    35.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    VT
    Van Hauwermeiren TimothyDirector
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    35.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002083206-26-000005
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jul 1, 2026
    Published
    Jul 1, 2026
    Ingested by INSIDER
    Nov 5, 03:50 UTC
    Last re-read
    Nov 5, 03:50 UTC

    Extracted facts

    Filer
    Tamayo Louis Edward
    Role
    Chief Financial Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Lexeo Therapeutics, Inc.
    Ticker
    LXEO
    Shares
    4,641
    Price per share
    $4.49
    Value
    $20,838
    Execution date (reported)
    Jul 1, 2026
    Owned after transaction
    97.0K shares
    Days from execution to publication
    0

    Calculation

    Value = shares × reported price per share

    • Shares: 4,641
    • Price: $4.49

    = $20,838

    What this establishes

    Tamayo Louis Edward filed this Form 4 reporting a open-market sale of LXEO on Jul 1, 2026. It became public on Jul 1, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Tamayo Louis Edwardcik:0002083206
    Issuer
    Lexeo Therapeutics, Inc.cik:0001907108

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.